Atg9a Inhibitors
The chemical class known as Atg9a Inhibitors encompasses a range of compounds that affect Atg9a indirectly by targeting various signaling molecules and cellular processes that are upstream or downstream in the autophagic pathway. Atg9a is a transmembrane protein that is essential for the formation and trafficking of autophagosomes, the cellular structures responsible for autophagy, a process of cellular degradation and recycling.
These chemicals exert their influence by modulating the activity of enzymes and complexes such as PI3K, mTOR, and V-ATPase, which play pivotal roles in the initiation, nucleation, and maturation of autophagosomes. For example, compounds like 3-Methyladenine, Wortmannin, and LY294002 inhibit the PI3K complex, which is critical for the induction of autophagy, thereby potentially limiting the availability or functionality of Atg9a in the autophagosome formation process. On the other hand, chemicals such as Bafilomycin A1 and Concanamycin A target the V-ATPase that is involved in the fusion of autophagosomes with lysosomes, a terminal step in autophagy. This step is important for the recycling of Atg9a to the trans-Golgi network, and its inhibition can thus impact the overall cycling and function of Atg9a.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $65.00 $261.00 | 113 | |
Inhibits class III phosphatidylinositol 3-kinase (PI3K), which is crucial for autophagosome formation, indirectly affecting Atg9a trafficking. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Acts as a PI3K inhibitor, thereby disrupting the PI3K complex involved in membrane nucleation, a process where Atg9a is implicated. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Another PI3K inhibitor that can impede the formation of autophagic vesicles, consequently impacting Atg9a function. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $168.00 | ||
Targets ubiquitin-specific peptidase 10 (USP10) and USP13, leading to the destabilization of Vps34 complexes, thereby influencing Atg9a. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Disrupts autophagosome-lysosome fusion, this impacts the recycling of Atg9a from autophagosomes to the trans-Golgi network. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Specific V-ATPase inhibitor that blocks autophagosome-lysosome fusion, indirectly affecting Atg9a recycling. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
Similar to Bafilomycin A1, inhibits V-ATPase, which can lead to disruption in autophagic flux and Atg9a dynamics. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Inhibits mTOR, a master regulator of autophagy, thus indirectly affects Atg9a by modulating the autophagy initiation process. | ||||||
MHY1485 | 326914-06-1 | sc-507522 | 10 mg | $140.00 | ||
An mTOR activator, hence by stimulating mTOR, it indirectly inhibits autophagy and could impact Atg9a's function in autophagosome formation. | ||||||
KU 0063794 | 938440-64-3 | sc-361219 | 10 mg | $209.00 | ||
Directly inhibits mTORC1 and mTORC2 complexes, leading to autophagy induction, which can affect Atg9a's role in autophagosome biogenesis. | ||||||